| 冯松叶,史香芬,卢晓静,等.白细胞介素抑制剂类生物制剂治疗斑块状银屑病的文献可视化分析[J].安徽医药,2023,27(12):2513-2519. |
| 白细胞介素抑制剂类生物制剂治疗斑块状银屑病的文献可视化分析 |
| Visualization and analysis of the literature on interleukin-inhibitor -based biologics for the treatment of plaque psoriasis |
| |
| DOI：10.3969/j.issn.1009-6469.2023.12.040 |
| 中文关键词: 银屑病 乌司奴单抗 司库奇尤单抗 依奇珠单抗 古赛奇尤单抗 白细胞介素抑制剂 可视化分析 文献计量学 |
| 英文关键词: Psoriasis Ustekinumab Secukinumab Ixekizumab Guselkumab Interleukin inhibitors Visualization analy. sis Bibliometrics |
| 基金项目:河南省高等学校重点科研项目计划( 19B350008) |
|
| 摘要点击次数: 848 |
| 全文下载次数: 647 |
| 中文摘要: |
| 目的分析白细胞介素( IL)抑制剂类生物制剂在斑块状银屑病治疗中的研究现状及热点。方法检索 2011年 1月 1日至 2022年 4月 30日在 Web of Science核心合集数据库发表的 IL抑制剂类生物制剂在斑块状银屑病治疗方面的相关研究，利用 CiteSpace5.8.R3软件进行文献的可视化分析，从发文量、国家 /地区、机构、作者、期刊等文献关键特征分析该领域的研究现状，通过文献共被引、关键词共现、聚类及突现分析该领域的知识基础、研究热点及前沿。结果共纳入文献 2 056篇，近 10年发文量呈逐年递增趋势，共计 104个国家 /地区的 545个机构参与了 IL抑制剂类药物治疗斑块状银屑病的研究，其中美国发文量 805篇，占总发文量的 39.15%居首位，且与德国、英国、瑞士、加拿大等有密切合作，发文最多的机构是瑞士诺华制药，发文最多的作者是德国汉堡艾本多夫医学中心的 Reich K，被引频次第一的作者是加拿大 Prob Med公司的 Papp KA，被引频次最高的期刊为 British Journal of Dermatology；该领域的研究热点主要为生物制剂治疗斑块状银屑病的作用机制、疗效及安全性研究，研究前沿为长期疗效及安全性研究、特殊人群研究、新型双特异性抗体的研究、自我给药研究及在其他疾病的应用研究等。结论近 10年来， IL抑制剂类生物制剂治疗斑块状银屑病发展迅速，研究主要集中在治疗的有效性和安全性上，未来更应该关注对特殊人群及真实世界的研究。 |
| 英文摘要: |
| Objective To analyze the current status and hot spots of interleukin inhibitor-based biologics in plaque psoriasis treat. ment.Methods Research studies related to interleukin-inhibitor-based biologics in the treatment of plaque psoriasis were retrievedfrom January 1, 2011, to April 30, 2022, published in the Web of Science Core Collection database. CiteSpace 5.8.R3 software wasused for the visual analysis of the literature to characterize the current status of research in the field in terms of key features of the lit.erature such as the number of publications, countries/region, institution, authors, and journals. The knowledge base, research hot spotsand frontiers of the field were analyzed by literature cocitation, keyword cooccurrence, clustering and bursting.Results A total of 2,056 publications have been included in the literature, and the number of publications has been increasing year by year in the past 10years. A total of 545 institutions from 104 countries/regions have participated in the research of interleukin-inhibitor biologics in thetreatment of plaque psoriasis, of which the United States has issued 805 publications, accounting for 39.15% of the total number ofpublications, and there is close cooperation with Germany, the United Kingdom, Switzerland, Canada, etc. The organization that has is.sued the most publications is Novartis Pharmaceuticals (Switzerland), the author with the most publications is Reich K of the Eppen.dorf Medical Center in Hamburg, Germany, the most frequently cited author is Papp KA of Prob Med, Canada, and the most frequentlycited journal is the British Journal of Dermatology. The research hot spots in this field mainly focus on the mechanism of action, effica.cy and safety of biologics for the treatment of plaque psoriasis, and the research frontiers are long-term efficacy and safety, special pop. ulations research, novel bispecific antibodies, self-administration research, and the application of research in other diseases.Conclu. sion In the past 10 years, interleukin-inhibitor-based biologics for the treatment of plaque psoriasis have developed rapidly, with re.search focusing on the efficacy and safety of the treatment, and more attention should be given to research in special populations and in the real world in the future. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
